Literature DB >> 34011136

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient.

Annie Harroche1, Thibaud Sefiane2, Maximilien Desvages3, Delphine Borgel3, Dominique Lasne3, Caterina Casari2, Ivan Peyron2, Laurent Frenzel1, Stéphanie Chhun4, Peter J Lenting5, Cécile Bally1.   

Abstract

Not available.

Entities:  

Year:  2021        PMID: 34011136     DOI: 10.3324/haematol.2021.278579

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  4 in total

Review 1.  Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?

Authors:  Patrick Ellsworth; Alice Ma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.

Authors:  Makoto Kaneda; Ryohei Kawasaki; Naoki Matsumoto; Hiroto Abe; Yoshihito Tashiro; Yuta Inokuchi; Hideyuki Yasuno; Mariko Sasaki-Noguchi; Tetsuhiro Soeda; Yasushi Yoshimura; Toshiaki Oka
Journal:  J Thromb Haemost       Date:  2021-09-28       Impact factor: 16.036

3.  Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A.

Authors:  Angelika Batorova; Ana Boban; Melen Brinza; Toshiko Lissitchkov; Laszlo Nemes; Irena Zupan Preložnik; Petr Smejkal; Nadezhda Zozulya; Jerzy Windyga
Journal:  J Med Life       Date:  2022-04

4.  Emicizumab state-of-the-art update.

Authors:  Johnny Mahlangu; Alfonso Iorio; Gili Kenet
Journal:  Haemophilia       Date:  2022-05       Impact factor: 4.263

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.